The RATinG (Risk Adapted Therapy in Acute GvHD) is the first trial to explore granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralization for the early treatment of participants with ...

The study uses an elegant CRISPR/Cas9 screening approach in a myeloid cell line to identify the underlying regulators of the alarmins S100A8 and S100A9, which amplify inflammation. This approach ...

The optimal management of pregnant women with a previous child affected by fetomaternal alloimmune thrombocytopenia remains unclear. Differences between the platelets of an unborn baby and their ...

Figure 1 Schematic representation of the protocol used for ex vivo expansion of alloantigen-specific regulatory T cells (Tregs). CD4 + CD25 hi CD127 − T cells [labeled with CellTrace Violet (CTV)] ...

A wide variety of alloantigen copy number is found amongst blood groups. In some cases, the copy number varies widely from donor to donor, while the amino acid sequence of the antigen is unchanged.

Briefly, BALB/c mice were transplanted with defined ratios of T cell-depleted BM and purified T cells from B6 mice, then given transgenic, bioluminescent, alloantigen-specific B6 T cells after initial ...

Lentiviral vectors (LV) are powerful and versatile vehicles for gene therapy. However, their complex biological composition challenges large‐scale manufacturing and raises concerns for in vivo ...

Cytotoxic CD8 T-cell responses against mismatched MHC class I alloantigen are the principal arm of the cellular response against a transplanted organ. How CD4 T cells deliver essential help for ...

Uniquely, alloantigen is recognised by two pathways: as intact antigen on the surface of donor antigen-presenting cells (direct) and as self-restricted processed allopeptide (indirect). The indirect ...